

Dialyse peritoneaaldialyse: aztreonam

	Wijziging kinetiek	Effect dialyse	Actie	Datum
Beslissing werkgroep	Ja	Nee	Ja	20 maart 2025

Literatuur

Onderbouwend	Bewijs	Effect	Opmerkingen
Gerig JS ea. Effect of hemodialysis and peritoneal dialysis on aztreonam pharmacokinetics. Kidney Int. 1984;26(3):308-18.	2	CAPD patiënten: na 1-malig aztreonam 1 g intraveneus in 2 min. was de $t_{1/2}$ 7.1 uur tijdens CAPD. De gemiddelde $t_{1/2}$ van aztreonam bij gezonde vrijwilligers is 1.7 tot 2.9 uur (volgens eerdere studies: Swabb 1982 en Mihindu 1983). Er werd 9.7% van dosis aztreonam verwijderd door CAPD. Aztreonam werd goed verdragen door alle HD- en CAPD-patiënten; er werden geen bijwerkingen of opvallende veranderingen in laboratoriumwaarden gevonden.	HD patiënten (n = 6) en CAPD patiënten (n = 6). Auteurs: "Hemodialysis and CAPD patients given aztreonam treatment should receive the standard dose of aztreonam as a loading dose, followed by one-fourth the loading dose at standard dose intervals. Hemodialysis patients should receive a supplemental dose equal to half their usual maintenance dose immediately after each dialysis session."

Overig	Opmerkingen
SmPC Azactam (december 2022)	Geen informatie over PD. In patients with severe renal failure (creatinine clearance less than 10 mL/min/1.73 m²), such as those supported by hemodialysis, the usual dose should be given initially. The maintenance dose should be one-fourth of the usual initial dose given at the usual fixed interval of 6, 8 or 12 hours. For serious or life-threatening infections, in addition to the maintenance doses, one-eighth of the initial dose should be given after each hemodialysis session.

Zoektermen

Pubmed

Datum: 23-12-2024

Search #	Zoektermen
#1	("aztreonam"[Supplementary Concept] OR "aztreonam" [MeSH Terms] OR "aztreonam"[Title/Abstract]) AND ("Renal Replacement Therapy"[Mesh] OR "Peritoneal Dialysis"[MeSH Terms] OR "Peritoneal Dialysis" [Title/Abstract])